Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Large Decline in Short Interest

by · The Cerbat Gem

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) saw a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 284,944 shares, a decrease of 27.1% from the December 31st total of 391,100 shares. Based on an average daily volume of 239,638 shares, the days-to-cover ratio is currently 1.2 days. Approximately 1.5% of the company’s stock are sold short. Approximately 1.5% of the company’s stock are sold short. Based on an average daily volume of 239,638 shares, the days-to-cover ratio is currently 1.2 days.

Artiva Biotherapeutics Stock Down 6.3%

Shares of NASDAQ:ARTV opened at $3.89 on Friday. The company has a market cap of $95.50 million, a price-to-earnings ratio of -1.51 and a beta of 2.92. The business has a 50 day moving average price of $4.19 and a 200 day moving average price of $3.54. Artiva Biotherapeutics has a twelve month low of $1.47 and a twelve month high of $7.36.

Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. Analysts anticipate that Artiva Biotherapeutics will post -4.95 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a research note on Friday, October 17th. Jefferies Financial Group raised Artiva Biotherapeutics to a “strong-buy” rating in a research report on Tuesday, November 18th. HC Wainwright upped their price target on Artiva Biotherapeutics from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. Wedbush raised their price objective on Artiva Biotherapeutics from $18.00 to $23.00 and gave the company an “outperform” rating in a research note on Friday, October 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $19.00.

Read Our Latest Stock Analysis on Artiva Biotherapeutics

Institutional Trading of Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ARTV. Bank of America Corp DE increased its holdings in shares of Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after purchasing an additional 11,190 shares during the period. Prelude Capital Management LLC acquired a new stake in Artiva Biotherapeutics during the third quarter worth about $41,000. Ground Swell Capital LLC bought a new position in Artiva Biotherapeutics during the second quarter valued at about $38,000. Y Intercept Hong Kong Ltd bought a new position in Artiva Biotherapeutics during the second quarter valued at about $48,000. Finally, Bridgeway Capital Management LLC acquired a new position in Artiva Biotherapeutics in the 2nd quarter valued at approximately $53,000.

Artiva Biotherapeutics Company Profile

(Get Free Report)

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.

Read More